Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1129-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data ; volume:21 ; number:1 ; day:25 ; month:4 ; year:2020 ; pages:1-10 ; date:12.2020
The journal of headache and pain ; 21, Heft 1 (25.4.2020), 1-10, 12.2020
- Creator
-
Ornello, Raffaele
Guerzoni, Simona
Baraldi, Carlo
Evangelista, Luana
Frattale, Ilaria
Marini, Carmine
Tiseo, Cindy
Pistoia, Francesca
Sacco, Simona
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-020-01113-6
- URN
-
urn:nbn:de:101:1-2020070515565685790783
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ornello, Raffaele
- Guerzoni, Simona
- Baraldi, Carlo
- Evangelista, Luana
- Frattale, Ilaria
- Marini, Carmine
- Tiseo, Cindy
- Pistoia, Francesca
- Sacco, Simona
- SpringerLink (Online service)
Other Objects (12)
Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
Real-Life Decision-Making
Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy
OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
Real-Life Decision-Making
Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy
OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
Real-Life Decision-Making
Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy
OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study